Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | ALPG | P10696 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | TDO2 | P48775 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 2/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8763308 | 0.89 | ESR1 (0.34) | — | |
| SCHEMBL29704594 | 0.81 | ALDH1A1 (0.39) | LMNASMN1; SMN2ALDH1A1TDP1HTT | |
| SCHEMBL21424438 | 0.79 | CES2 (0.31) | — | |
| SCHEMBL22811766 | 0.79 | CES2 (0.31) | — | |
| SCHEMBL2936982 | 0.78 | TRPA1 (0.41) | LMNAALDH1A1HPGD | |
| SCHEMBL576267 | 0.75 | IDO1 (0.50) | ALDH1A1IDO1TDO2HTTACHE | |
| SCHEMBL575745 | 0.75 | IDO1 (0.41) | ALDH1A1IDO1TDO2HTTACHE | |
| SCHEMBL21424455 | 0.72 | CYP11B1 (0.35) | — | |
| SCHEMBL22811772 | 0.72 | CYP11B1 (0.35) | — | |
| SCHEMBL8088810 | 0.71 | LMNA (0.46) | LMNASMN1; SMN2ALDH1A1ALPGTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009392-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-01-13 | — | — | US | disclosed |
| US-20110009392-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-01-13 | — | — | US | disclosed |
| WO-2009020580-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009392-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | LMNA 676/4885SMN1; SMN2 470/4885ALDH1A1 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.